EGFR and non-small cell lung carcinoma: Initial subgroup analysis of IMpower-150 trial indicated potential PFS and OS benefits from triple therapy compared to bevacizumab plus chemotherapy among EGFR mutation NSCLC patients (Nogami et al., 2022).